Comparison between treatment options in patients over the age of 70 years with AML

**Cohort**

980 Acute myeloid leukemia (AML) patients; median age 75.6 (70-95.7) years

**Treatment options**

1. **High-intensity** (daunorubicin/cytarabine or equivalent) — 360 (36.7%)
2. **Hypomethylating agent (HMA)** — 255 (26.0%)
3. **Low-intensity** (low-dose cytarabine or similar without hypomethylating agents) — 91 (9.3%)
4. **Supportive care therapy** (including hydroxyurea) — 274 (28.0%)

**Median follow-up**

25 months

**Median overall survival of the entire cohort**

7.1 months

**Results**

**Median overall survival**

1. **High-intensity** — 10.8 months
2. **HMA** — 14.4 months
3. **Low-intensity** — 5.9 months
4. **Supportive care therapy** — 2.1 months

A significant survival benefit using frontline HMA

HR = 1.35, 95% CI, 1.10-1.65; P = .004

HR = 2.01, 95% CI, 1.53-2.62; P < .0001

HR = 2.94, 95% CI, 2.39-3.61; P < .0001

Talati et al., Haematologica, 2020